Search Results

TaiMed Biologics, an innovation-driven biotech company dedicated to serving unmet healthcare needs, has announced favorable results and the successful completion of the sentinel group in its phase 1b/2a clinical study evaluating its groundbreaking new treatment for HIV — Long-Acting TMB-365/TMB-380 mAb Combination Maintenance HIV Therapy — initially unveiled at its investor conference on September 6.

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.

This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.